Evidence map›Paper›PMID 37046785›Full record

ArticleCancers2023

Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective Study

Magnus Holm, Peter Vestergaard, Morten Møller Poulsen, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Mette Bay, Lars Rolighed, Stefano Londero, Henrik Baymler Pedersen, Christoffer Holst Hahn and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Genes · 2025
    Review
  3. Review
  4. Review
  5. Heritable hyperparathyroidism: Genetic insights and clinical implications.Best practice & research. Clinical endocrinology & metabolism · 2025
    Review
  6. Cancers · 2025
    Article
  7. Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  8. What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  9. Article
  10. Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  11. Primary Hyperparathyroidism in MEN2 Syndromes.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  12. Familial states of primary hyperparathyroidism: an update.Journal of endocrinological investigation · 2024
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Magnus HolmDepartment of ORL Head & Neck Surgery and Audiology, Odense University Hospital, 5000 Odense, Denmark.ORCID 0000-0003-2470-8196
Peter VestergaardSteno Diabetes Center North Denmark, Aalborg University Hospital, 9100 Aalborg, Denmark.
Morten Møller PoulsenDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
Åse Krogh RasmussenDepartment of Endocrinology and Metabolism, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Ulla Feldt-RasmussenDepartment of Endocrinology and Metabolism, Copenhagen University Hospital, 2100 Copenhagen, Denmark.ORCID 0000-0002-5903-3355
Mette BayDepartment of ORL Head & Neck Surgery and Audiology, Odense University Hospital, 5000 Odense, Denmark.
Lars RolighedDepartment of ORL Head & Neck Surgery, Aarhus University Hospital, 8200 Aarhus, Denmark.
Stefano LonderoDepartment of ORL Head & Neck Surgery, Aarhus University Hospital, 8200 Aarhus, Denmark.
Henrik Baymler PedersenDepartment of ORL Head & Neck Surgery, Aalborg University Hospital, 9100 Aalborg, Denmark.
Christoffer Holst HahnDepartment of ORL Head & Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Klara Bay RaskDepartment of ORL Head & Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Heidi Hvid NielsenDepartment of Clinical Biochemistry, Zealand University Hospital, 4000 Roskilde, Denmark.
Mette GaustadnesDepartment of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
Maria Caroline RossingDepartment of Endocrinology and Metabolism, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Anne Pernille HermannDepartment of Endocrinology, Odense University Hospital, 5000 Odense, Denmark.
Christian GodballeDepartment of ORL Head & Neck Surgery and Audiology, Odense University Hospital, 5000 Odense, Denmark.
Jes Sloth MathiesenDepartment of ORL Head & Neck Surgery and Audiology, Odense University Hospital, 5000 Odense, Denmark.ORCID 0000-0002-9770-3188
Aarhus University Hospital · DKCopenhagen University Hospital · DKOdense University Hospital · DKUniversity of Southern Denmark · DKAalborg University Hospital · DKSteno Diabetes Centers · DKUniversity of Copenhagen · DKZealand University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies of primary hyperparathyroidism (PHPT) in multiple endocrine neoplasia type 2A (MEN 2A) shows divergence in frequency, disease definition, reporting of clinical characteristics and traces of selection bias. This is a nationwide population-based retrospective study of PHPT in MEN 2A, suggesting a representative frequency, with complete reporting and a strict PHPT definition. The Danish MEN 2A cohort 1930-2021 was used. Of 204 MEN 2A cases, 16 had PHPT, resulting in a frequency of 8% (CI, 5-12). Age-related penetrance at 50 years was 8% (CI, 4-15). PHPT was seen in the American Thyroid Association moderate (ATA-MOD) and high (ATA-H) risk groups in 62% and 38% of carriers, respectively. Median age at PHPT diagnosis was 45 years (range, 21-79). A total of 75% were asymptomatic and 25% were symptomatic. Thirteen underwent parathyroid surgery, resulting in a cure of 69%, persistence in 8% and recurrence in 23%. In this first study with a clear PHPT definition and no selection bias, we found a lower frequency of PHPT and age-related penetrance, but a higher age at PHPT diagnosis than often cited. This might be affected by the Danish

Indexed as

Denmarkhypercalcemiamultiple endocrine neoplasia type 2Anational cohortprimary hyperparathyroidismREarranged during Transfection

Identifiers

PMID37046785
PMCPMC10093219
OpenAlexW4362582535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.